BeStock  
Stocks › Biotechnology › ATTO

Attovia Therapeutics ATTO

US equityMarket cap rank #3395Biotechnology
$15.10 −$0.48 (-3.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.10 0.00%
Open$15.40
Prev close$15.58
Day range$14.80 – $15.46
Volume372.2K
Market cap$690.26M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership54.5%+54.53 pts vs. prior quarter
Institutions holding28+28 vs. prior quarter
Insider trades (recent)17 buys / 1 sellsNet buying
Short interest3.48% of floatDays to cover 4.5 · as of 30 Oct 2026
Short-sale volume share24.1%5-day average of daily volume

Short-sale volume as % of daily volume

11%19%26%33%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$911.7K (4 inflow days, 16 outflow days).

Net flow by order size, last 20 sessions

−$366.3KSuper−$545.4KBig−$692.4KMid−$2.4MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 42.8% of shares outstanding.

Largest holders

  • Frazier Life Sciences Management, LP15.27%
  • venBio LLC9.16%
  • Alamar Biosciences, Inc.7.07%
  • Deep Track Capital, LP7.03%
  • Goldman Sachs Asset Management, L.P.4.31%
  • Sanofi2.37%
  • Redmile Group, LLC2.15%
  • Vanguard Capital Management, LLC1.71%

By investor type

  • VC/PE Fund31.45%
  • Public Company10.56%
  • Mutual Fund10.24%
  • Hedge Fund2.28%
  • Individual/Insider1.58%
  • Private Company0.00%

Reported short interest has risen from 1.19% to 3.48% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Charles Schwab Investment Management Mutual Fund 2026/Q3 +100,603 0.2%
Sanofi Public Company 2026/Q3 +1,082,855 2.4%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +782,012 1.7%
Federated Hermes, Inc. Mutual Fund 2026/Q3 +700,000 1.5%
FMR Mutual Fund 2026/Q3 +323,669 0.7%
BlackRock Mutual Fund 2026/Q3 +265,397 0.6%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +206,176 0.5%
UBS Asset Management Mutual Fund 2026/Q3 +183,751 0.4%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +42,725 0.1%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +38,451 0.1%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +20,495 0.0%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +90,644 0.2%
Hartford Funds Management Company, LLC Mutual Fund 2026/Q3 +12,400 0.0%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +2,430 0.0%
Wellington Management Group Mutual Fund 2026/Q3 +1,800 0.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
5 Aug 2026 Sanofi Private Acquisition +300,000 $17.00 1,082,855
5 Aug 2026 Sanofi Derivative Exercise and Retained +782,855 – 1,082,855
5 Aug 2026 Redmile Group, LLC Private Acquisition +200,000 $17.00 982,854
5 Aug 2026 Redmile Group, LLC Derivative Exercise and Retained +782,854 – 982,854
5 Aug 2026 venBio LLC Private Acquisition +382,352 $17.00 4,181,367
5 Aug 2026 venBio LLC Derivative Exercise and Retained +3,799,015 – 4,181,367
5 Aug 2026 Deep Track Capital, LP Derivative Exercise and Retained +1,957,138 – 1,957,138
5 Aug 2026 Frazier Life Sciences Management, LP Private Acquisition +588,235 $17.00 6,154,213
5 Aug 2026 Frazier Life Sciences Management, LP Derivative Exercise and Retained +5,490,629 – 6,154,213
4 Aug 2026 The Goldman Sachs Group, Inc. Intent to Sell (Form 144) -105,807 $21.00 –
4 Aug 2026 Goldman Sachs Asset Management, L.P. Open Market Derivative Acquisiti +105,807 – 105,807
3 Aug 2026 Sanofi Initial Statement of Beneficial +0 – 782,855
3 Aug 2026 Mitchell Gold Independent Director Other Derivative Acquisition +27,000 $17.00 27,000
3 Aug 2026 Mitchell Gold Independent Director Initial Statement of Beneficial +0 – 19,913
3 Aug 2026 Angie You Independent Director Other Derivative Acquisition +27,000 $17.00 27,000
3 Aug 2026 John Smither Independent Director Initial Statement of Beneficial +0 – 72,792
3 Aug 2026 Hubert Chen Chief Medical Officer Other Derivative Acquisition +140,000 $17.00 140,000
3 Aug 2026 Broad Street Principal Investments, L.L.C. Initial Statement of Beneficial +0 – 855,179
3 Aug 2026 Tao Fu Chief Executive Officer Other Derivative Acquisition +538,300 $17.00 538,300
3 Aug 2026 Tao Fu Chief Executive Officer Initial Statement of Beneficial +0 – 803,436

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 1,587,537 3.5% 4.5
15 Oct 2026 1,453,089 3.2% 3.5
30 Sep 2026 1,649,612 3.6% 3.0
15 Sep 2026 831,090 1.8% 4.0
31 Aug 2026 648,541 1.5% 3.1
14 Aug 2026 511,865 1.2% 1.0

Discussion

No comments yet — be the first to weigh in on ATTO.

Sign in to join the discussion.

Scroll to Top